🇺🇸 FDA
Pipeline program

liraglutide

NN8022-1922

Phase 3 small_molecule completed

Quick answer

liraglutide for Metabolism and Nutrition Disorder is a Phase 3 program (small_molecule) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).

Program details

Company
Novo Nordisk A/S
Indication
Metabolism and Nutrition Disorder
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials